Zimmer Biomet (NYSE:ZBH) Share Price Crosses Below Fifty Day Moving Average – Time to Sell?

Posted by Brenda Bartman on Oct 17th, 2026

Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report)’s share price passed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $95.34 and traded as low as $93.23. Zimmer Biomet shares last traded at $94.5130, with a volume of 1,858,632 shares traded.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZBH. UBS Group reissued a “buy” rating and issued a $120.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Citigroup reissued a “neutral” rating on shares of Zimmer Biomet in a report on Monday, October 5th. Truist Financial increased their price target on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a report on Thursday, August 6th. Sanford C. Bernstein lifted their price target on shares of Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Finally, Canaccord Genuity Group raised their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research note on Monday, August 10th. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $103.33.

Get Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Price Performance

The company has a fifty day simple moving average of $95.31 and a two-hundred day simple moving average of $91.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market capitalization of $18.10 billion, a price-to-earnings ratio of 23.09, a P/E/G ratio of 1.78 and a beta of 0.49.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the prior year, the business posted $2.07 earnings per share. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.0%. The ex-dividend date is Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 23.36%.

Insider Transactions at Zimmer Biomet

In other news, insider Kevin R. Thornal sold 5,691 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Chad Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Zimmer Biomet during the second quarter worth about $1,344,282,000. State Street Corp grew its position in Zimmer Biomet by 0.6% in the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock valued at $766,343,000 after buying an additional 52,044 shares in the last quarter. Primecap Management Co. CA acquired a new stake in shares of Zimmer Biomet in the 2nd quarter worth approximately $328,578,000. Dimensional Fund Advisors LP lifted its position in Zimmer Biomet by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock worth $201,082,000 after purchasing an additional 24,208 shares during the period. Finally, Bank of America Corp DE acquired a new position in shares of Zimmer Biomet during the 2nd quarter valued at $187,480,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet Holdings, Inc (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. The company develops, manufactures and markets products used in orthopedic surgery, including total and partial knee, hip and shoulder replacement systems, sports medicine products, extremities, trauma devices and related surgical technologies.

Its portfolio also includes orthopedic surgical equipment, robotic- and computer-assisted technologies, biologics and other solutions designed to support joint reconstruction, spine procedures and dental applications.